Closed · RFA-DK-20-509 · CFDA 93.847 · Discretionary
Limited Competition for Continuation of the Integrated Islet Distribution Program (U24 Clinical Trial Not Allowed)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $2M
- Award range
- Closed
- Status
- February 9, 2021
- Close date
- -
- Expected awards
The verdict
Limited Competition for Continuation of the Integrated Islet Distribution Program (U24 Clinical Trial Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Up to $2,000,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- up to $2M
- award range
- Closed
- application status
- 93.847
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Limited Competition for Continuation of the I… is closed (last close February 9, 2021). The parent program page for CFDA 93.847 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed February 9, 2021
Instrument
Cooperative Agreement
Description
This Funding Opportunity Announcement (FOA) invites one application from the Program Director(s)/Principal Investigator(s) of the current Integrated Islet Distribution Program (IIDP) to renew the program andmaintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research.The IIDP facilitates the distribution of human islets to biomedical researchers byestablishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. The programmanages an application process to establish investigator eligibility to receive islet shipments, informs investigators of islet availability, manages a cost recovery system through fees collected from islet recipients, and oversees standardized phenotypic and genotypic analyses of islet preparations distributed throughout theIIDP network. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapiesfor the prevention and treatment of diabetes.
Catch-all / unrestricted eligibility mark · RFA-DK-20-509
Grants.gov marks Limited Competition for Continuation of the I… with a catch-all / unrestricted eligibility code (Others (see official listing text)). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Food and Nutrition · Health (FN;HL). Only 187 other National Institutes of Health listings share this exact eligibility-code string (2% of 12,420).
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Diabetes, Endocrine, and Metabolic Disease Research
National Institutes of Health
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Limited Competition for Continuation of the I… is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.847 may publish future NOFOs under the same assistance listing. Open program
- Diabetes, Endocrine, and Metabolic Disease Re… indexes 72 Grants.gov listings in this extract. Program profile
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |